A new clinical study shows that an inhibitor of Fas ligand (FasL), also called CD95 ligand (CD95L), led to a faster recovery of COVID-19 patients and reduced mortality.
FasL inhibitor speeds recovery and reduces mortality in severe COVID-19 patients
- Post author:
- Post published:November 14, 2024
- Post category:uncategorized